The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...

The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new publication in The Proceedings of the ...

Many cancers exhibit high levels of the reverse transcriptase enzyme. Single-agent lamivudine, a reverse transcriptase inhibitor, stopped disease progression in over 25% of patients with fourth-line ...

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.

The doravirine and islatravir pair could offer an alternative to INSTI-based treatment opt ...

A recent study confirms lenacapavir's effectiveness against HIV and highlights the capsid as a promising drug target despite resistance.

Pseudoscience has recently re-emerged in the U.S. While much of it concerns vaccines, an "oldie" is again making the rounds: HIV is neither the cause nor the sole cause of AIDS. This nonsense has been ...

HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...